Pharmosa Biopharm Inc. (TPEX: 6875)

Market Cap	7.64B
Revenue (ttm)	50.52M
Net Income (ttm)	-292.93M
Shares Out	129.02M
EPS (ttm)	-2.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,193
Open	59.20
Previous Close	59.20
Day's Range	56.50 - 59.20
52-Week Range	48.25 - 125.50
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It is developing L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei Ci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6875